During the last session, Standard BioTools Inc (NASDAQ:LAB)’s traded shares were 0.69 million, with the beta value of the company hitting 1.57. At the end of the trading day, the stock’s price was $1.82, reflecting an intraday gain of 4.00% or $0.07. The 52-week high for the LAB share is $3.04, that puts it down -67.03 from that peak though still a striking 33.52% gain since the share price plummeted to a 52-week low of $1.21. The company’s market capitalization is $677.51M, and the average intraday trading volume over the past 10 days was 1.33 million shares, and the average trade volume was 1.78 million shares over the past three months.
Standard BioTools Inc (LAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. LAB has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Standard BioTools Inc (NASDAQ:LAB) trade information
Standard BioTools Inc (LAB) registered a 4.00% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 4.00% in intraday trading to $1.82, hitting a weekly high. The stock’s 5-day price performance is -4.21%, and it has moved by -0.55% in 30 days. Based on these gigs, the overall price performance for the year is -10.78%. The short interest in Standard BioTools Inc (NASDAQ:LAB) is 13.31 million shares and it means that shorts have 7.61 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.25, which implies an increase of 44.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.25 and $3.25 respectively. As a result, LAB is trading at a discount of -78.57% off the target high and -78.57% off the low.
Standard BioTools Inc (LAB) estimates and forecasts
Statistics show that Standard BioTools Inc has outperformed its competitors in share price, compared to the industry in which it operates. Standard BioTools Inc (LAB) shares have gone down -2.15% during the last six months, with a year-to-date growth rate more than the industry average at 53.66% against 24.90.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 8.72%. While earnings are projected to return 62.06% in 2025, the next five years will return -8.06% per annum.
LAB Dividends
Standard BioTools Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Standard BioTools Inc insiders own 1.86% of total outstanding shares while institutional holders control 73.29%, with the float percentage being 74.68%. CASDIN CAPITAL, LLC is the largest shareholder of the company, while 187.0 institutions own stock in it. As of 2024-06-30, the company held over 63.96 million shares (or 17.1782% of all shares), a total value of $113.21 million in shares.
The next largest institutional holding, with 58.65 million shares, is of VIKING GLOBAL INVESTORS LP’s that is approximately 15.7524% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $103.81 million.
